久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

澳大利亞AMBRI
澳大利亞是納米技術(shù)研究領(lǐng)域的領(lǐng)軍者，1987年悉尼大學(xué)和AMBRI Pty有限公司（一家悉尼生物技術(shù)公司）的一組澳大利亞科學(xué)家制出了世界上第一臺(tái)納米儀。這種儀器體形極小，其部件僅為分子大小，還可以用來(lái)對(duì)人體內(nèi)部做醫(yī)療檢查，對(duì)污染物進(jìn)行分析，或者用來(lái)支持微型計(jì)算機(jī)。AMBRI目前正致力于生物傳感器的商業(yè)化，將它用作一種主要的醫(yī)療診斷工具。

AMBRI Limited has operated since the late 1990s as a technology development Company focused solely on commercializing its patented Ion Channel Switch (ICS) technology as the basis of new biosensor products for medical and industrial applications. In 2006 the Company broadened its strategy to include the acquisition of new businesses with revenue and profit streams.

AMBRI listed on the Australian Stock Exchange in August 2001(ASX code: ABI) and the funds raised then and in subsequent equity placements have been applied to an escalating R&D effort. After missing several major development milestones and experiencing serious budget overruns, the Company implemented cost reduction measures, most significantly in February 2005 and again in early 2006. The R&D effort in 2006, despite being very much scaled back, produced promising new opportunities for the biosensor technology, which are the subject of a scientific paper published in August 2007.

Other than biosensors for diabetes testing, biosensors generally have not achieved analyst predictions of billion dollar sales in medical, environmental and industrial testing applications. The contenders pursuing these new markets have so far struggled to overcome technical challenges, but the large commercial opportunities continue to inspire a very substantial industry effort to find technological breakthroughs.

To progress the AMBRI technology to a commercial ready biosensor platform requires skills and resources beyond AMBRI and so the Company has stopped its own R&D and is seeking to progress the commercialization effort only through an appropriate partnership.

Ambri shareholders can look forward to AMBRI emerging in the short term as a business that is revenue and profit generating, arising from the current M&A effort and in the longer term have further shareholder value uplift from partnership or license-out arrangements of the AMBRI biosensor technology.